Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock*-Reference-Cited by-同舟云学术

Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock*

Published:2020-07-28 Issue:10 Volume:48 Page:1513-1520
ISSN:0090-3493
Container-title:Critical Care Medicine
language:en
Short-container-title:

Author:

Atreya Mihir R.,Whitacre Brynne E.,Cvijanovich Natalie Z.,Bigham Michael T.,Thomas Neal J.,Schwarz Adam J.,Weiss Scott L.,Fitzgerald Julie C.,Allen Geoffrey L.,Lutfi Riad,Nowak Jeffrey E.,Quasney Michael W.,Shah Amy S.,Wong Hector R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference33 articles.

1. Global epidemiology of pediatric severe sepsis: The sepsis prevalence, outcomes, and therapies study.;Weiss;Am J Respir Crit Care Med,2015

2. Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial.;Nadel;Lancet,2007

3. The PCSK9 decade.;Lambert;J Lipid Res,2012

4. The evolving future of PCSK9 inhibitors.;Rosenson;J Am Coll Cardiol,2018

5. PCSK9 is a critical regulator of the innate immune response and septic shock outcome.;Walley;Sci Transl Med,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside;Signal Transduction and Targeted Therapy;2024-01-08

2. Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study;BMC Emergency Medicine;2023-10-31

3. Targeting PCSK9 to tackle cardiovascular disease;Pharmacology & Therapeutics;2023-09

4. MiR-15b-5p and PCSK9 inhibition reduces lipopolysaccharide-induced endothelial dysfunction by targeting SIRT4;Cellular & Molecular Biology Letters;2023-08-16

5. SERUM SOLUBLE ENDOGLIN IN PEDIATRIC SEPTIC SHOCK–ASSOCIATED MULTIPLE ORGAN DYSFUNCTION SYNDROME;Shock;2023-07-25